Haematology News and Research RSS Feed - Haematology News and Research

Beckman Coulter’s new DxH 500 haematology system installed at University of Chester’s Institute of Medicine

Beckman Coulter’s new DxH 500 haematology system installed at University of Chester’s Institute of Medicine

Beckman Coulter has installed the first DxH 500 haematology analyser in the UK at the University of Chester’s Institute of Medicine on the Countess of Chester Health Park. [More]
Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting

Leading experts in iron deficiency to participate in 3rd European Iron Academy meeting

The 3rd European Iron Academy (EIA) will take place on the 12th and 13th September 2016 in Berlin, Germany, and will bring together over 450 clinicians with an interest in iron deficiency. [More]
NICE MIB offers SD-IORT using Xoft Axxent electronic brachytherapy system for early stage breast cancer patients

NICE MIB offers SD-IORT using Xoft Axxent electronic brachytherapy system for early stage breast cancer patients

NICE (National Institute for Health and Care Excellence) has announced a new Medtech Innovation Briefing (MIB) stating that NHS doctors and commissioners may consider Single Dose Intraoperative Radiotherapy (SD-IORT) using the Xoft Axxent electronic brachytherapy system with ORL managed service as a treatment option for early stage breast cancer patients. [More]
Specialty pharmaceuticals: an interview with David Moran, Clinigen SP

Specialty pharmaceuticals: an interview with David Moran, Clinigen SP

Specialty pharmaceuticals as a category has its origins in the 1970s with complex treatments being developed for disease areas such as cancer, HIV and haemophilia and what characterises a specialty pharmaceutical product is that it will be high touch, high complexity or high cost and is often associated with the treatment of rare or orphan conditions. These products require a considerable amount of expertise, innovation and technology and can be expensive as a result. [More]
Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. [More]
Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated benefits. [More]
Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study. [More]
One in 10 people in UK believed to be vitamin B12 deficient

One in 10 people in UK believed to be vitamin B12 deficient

One in 10 people in the UK are believed to be deficient in vitamin B12 – that’s an astonishing six million people suffering from the consequences of having less than the optimum amount of B12 in their system. [More]
CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union. [More]
Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders to discuss role of cyclophosphamide in the field of HSCT

Key opinions leaders in the field of haematopoetic stem cell transplantation (HSCT) will address the role of Cyclophosphamide, an anti-cancer chemotherapy drug, during the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that will welcome more than 4,500 delegates in the host city of Valencia, Spain from the 3rd to the 6th of April 2016. [More]
Real-life data show feasibility of imatinib discontinuation in CML

Real-life data show feasibility of imatinib discontinuation in CML

Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment. [More]
Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients. [More]
New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

New FDA approval expands use of AstraZeneca's Faslodex for women with HR+, HER2- metastatic breast cancer

AstraZeneca today announced that the US Food and Drug Administration has approved a new indication in the US, expanding the use of Faslodex (fulvestrant) to include use in combination with Ibrance (palbociclib). [More]
Potential link between PLCD and ALL could offer new targets for cancer prevention research

Potential link between PLCD and ALL could offer new targets for cancer prevention research

A potential correlation between pre-labor cesarean delivery (PLCD) and acute lymphoblastic leukemia (ALL) could offer new targets for cancer prevention research, according to new research from the Masonic Cancer Center, University of Minnesota. [More]
Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Lenalidomide trials show potential for expanding lymphoma, leukaemia indications

Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia-lymphoma or peripheral T-cell lymphoma. [More]
Beckman Coulter Releases Compact DxH 500 Hematology System with CE Mark

Beckman Coulter Releases Compact DxH 500 Hematology System with CE Mark

Beckman Coulter Diagnostics has released the DxH 500 haematology system with CE Mark, an open-vial instrument offering a throughput of up to 60 samples per hour. [More]
New personalized DNA-based digital assay has potential to dramatically impact CML management

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued. [More]
Simple blood test could predict relapse in AML patients

Simple blood test could predict relapse in AML patients

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. [More]
Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan has today launched a new tissue typing method that could significantly improve stem cell transplant outcomes. [More]
Toxins in staphylococcus bacteria can help cancer cells gain control over healthy cells

Toxins in staphylococcus bacteria can help cancer cells gain control over healthy cells

Our skin is covered in millions of bacteria and most of them help keep us healthy. However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells. [More]
Advertisement
Advertisement